Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
Guselkumab showed no clear difference in proportion of participants with adverse effects serious or severe… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
Secukinumab probably leads to higher proportion of participants with adverse effects serious or severe… compared with placebo (moderate certainty).
1 finding from 1 review
Harms: non-serious adverse effects (headache, discomfort, loosening of temporary anchorage devices) · Adolescents and adults with malocclusion undergoing orthodontic treatment with fixed or removable appliances
Light vibrational forces (LVF) showed no clear difference in harms: non-serious adverse effects (headache, discomfort, loosening… compared with conventional orthodontic appliance treatment (placebo or no adjunct); GRADE not reported.
1 finding from 1 review
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with psychosis
1 finding from 1 review
Adverse effects sufficient to stop treatment · Children aged 6 to 18 years with ASD
Memantine showed no clear difference in adverse effects Assessed by the study authors as those that were… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Adverse effects (sores in the mouth, cramps, bloating, constipation, flatulence, loose stool or diarrhoea) · adults
1 finding from 1 review
Patterns of adverse effects (sores in the mouth, cramps, bloating, constipation, flatulence, and loose stool or diarrhoea) were similar for both groups. Bader 2013.
1 study · 669 participants
GRADE not reported
Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ difficulty with concentration/concentration… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes adverse effects/events: extrapyramidal symptoms ‐ medium termNumber… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · patients with motion sickness
Antihistamines may leads to higher adverse effects: sedation Assessed by: adverse effect questionnaire… compared with placebo (low certainty).
1 finding from 1 review
Adverse events including maternal pregnancy complications, foetal complications and adverse effects of thyroxine · subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism
Thyroxine led to lower adverse events including maternal pregnancy complications, foetal… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects: Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects:Parkinsonism (tremor) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review